We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A single dose of Regeneron’s COVID-19 antibody cocktail, REGEN-COV, slashed the risk of contracting the coronavirus by 81.6 percent up to eight months after treatment in a phase 3 trial. Read More
Two U.S. subsidiaries of Indian generics company Sun Pharmaceutical Industries have reached settlements totaling $85 million with plaintiffs in the companies’ drug-pricing antitrust litigation, said Sun in a statement. Read More
Can the federal government force drugmakers to participate in the controversial 340B drug discount program, punishing them with fines if they don’t? Read More
Since 2016, the number of businesses and clinics selling stem cell therapies has quintupled, says a University of California at Irvine professor. Read More
Emergent BioSolutions said, “These are mutually agreed-upon terminations for convenience and neither party is alleging breach of default by the other.” Read More
Following a year in which vaccine manufacturing plant Emergent BioSolutions spent many months in the headlines for botching 75 million Johnson & Johnson (J&J) COVID-19 vaccines, the federal government and the troubled company have parted ways. Read More
House Democrats Friday abruptly postponed a vote on the amended $1.85 trillion Build Back Better Act, with compromise, scaled-back provisions aimed at reducing the price of prescription drugs. Read More
The GAO’s assessment found that “14 of the 18 establishments that manufacture COVID-19 vaccines had been previously inspected at least once” within the past decade. Read More
Despite pleas for approval during a public comment period, the FDA’s Psychopharmacologic Drugs Advisory Committee failed yesterday to recommend Levo Therapeutics’ intrasanal carbetocin — an oxytocin analogue delivered via a spray pump — for treatment of hyperphagia and related anxiety in children with a rare genetic disorder, Prader-Willi Syndrome. Read More
House Democrats were expected to vote as soon as last night on the revised Build Back Better Act — including compromise provisions meant to lower the price of prescription drugs. Read More